Abstract
To determine the maximal tolerated dose of bortezomib with concurrent external beam radiation therapy in patients with incurable solid malignant tumors requiring palliative therapy. An open label, dose escalation, phase I clinical trial evaluated the safety of three dose levels of bortezomib administered intravenously (1.0 mg/m(2), 1.3 mg/m(2), and 1.6 mg/m(2)/ dose) once weekly with concurrent radiation in patients with histologically confirmed solid tumors and a radiographically appreciable lesion suitable for palliative radiation therapy. All patients received 40 Gy in 16 fractions to the target lesion. Dose-limiting toxicity was the primary endpoint, defined as any grade 4 hematologic toxicity, any grade ≥3 nonhematologic toxicity, or any toxicity requiring treatment to be delayed for ≥2 weeks. A total of 12 patients were enrolled. Primary sites included prostate (3 patients), head and neck (3 patients), uterus (1 patient), abdomen (1 patient), breast (1 patient), kidney (1 patient), lung (1 patient), and colon (1 patient). The maximum tolerated dose was not realized with a maximum dose of 1.6 mg/m(2). One case of dose-limiting toxicity was appreciated (grade 3 urosepsis) and felt to be unrelated to bortezomib. The most com...Continue Reading
References
May 1, 1995·Immunity·M A ReadT Collins
Sep 9, 1994·Cell·V J PalombellaT Maniatis
Nov 1, 1996·Science·A A Beg, D Baltimore
Dec 6, 1996·Science·R W KingM W Kirschner
Dec 6, 1996·Science·C J Sherr
Jun 27, 2003·The New England Journal of Medicine·Paul G RichardsonKenneth C Anderson
Sep 15, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G Varuni KondaguntaRobert J Motzer
Jun 17, 2005·The New England Journal of Medicine·Paul G RichardsonUNKNOWN Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators
Oct 13, 2006·Cancer·David P RyanJoseph P Eder
Nov 1, 2006·Cancer·David P RyanJames C Cusack
Jan 17, 2007·Cancer Biology & Therapy·Charles N WeberAnjali K Gupta
Jun 19, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jens VoortmanGiuseppe Giaccone
May 8, 2008·Archives of Gynecology and Obstetrics·Serra KamerAdam P Dicker
Jul 3, 2008·World Journal of Urology·Wengang CaoCharles J Rosser
Aug 14, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Callum M SlossJames C Cusack
Citations
Aug 24, 2013·Radiation Oncology·Christopher D LaoBruce G Redman
Dec 5, 2012·Vaccine·Peter L SternMark H Einstein
Nov 17, 2011·Cancer Letters·Chao-Yuan HuangKuen-Feng Chen
Jan 17, 2012·International Journal of Radiation Oncology, Biology, Physics·Gregory J KubicekAdam P Dicker
Mar 8, 2014·Clinical Oncology : a Journal of the Royal College of Radiologists·E J SearleI J Stratford
Apr 8, 2016·Expert Opinion on Investigational Drugs·Paolo Bossi, Salvatore Alfieri
Mar 25, 2014·Endocrine-related Cancer·Daniel E Johnson
Mar 6, 2018·Neurology India·Paresh K Doshi
Mar 27, 2018·Surgical Neurology International·Majed AldehriSarah Hescham
Jul 25, 2012·Surgical Neurology International·Tejas SankarClement Hamani
May 18, 2013·Surgical Neurology International·Jean-Jacques LemaireAntonio De Salles
Oct 8, 2014·Surgical Neurology International·Julio Leonardo Barbosa PereiraAntonio De Salles
Dec 7, 2018·Hematology·Tanya M Wildes, Kenneth C Anderson
Sep 17, 2017·Oncotarget·Eric DeutschSofia Rivera
Mar 1, 2012·Expert Review of Molecular Diagnostics·Yu-Chang LiuJeng-Jong Hwang
Sep 29, 2020·Frontiers in Oncology·Shuhua Zheng, Wensi Tao
Nov 12, 2021·Der Radiologe·Laila König, Klaus Herfarth